中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Association of the duration of systemic inflammatory response syndrome with infectious pancreatic necrosis at the initial stage of acute pancreatitis

DOI: 10.3969/j.issn.1001-5256.2021.03.029
  • Received Date: 2020-08-27
  • Accepted Date: 2020-10-20
  • Published Date: 2021-03-20
  •   Objective  To investigate the potential association between early-stage inflammatory response and late-stage infectious pancreatic necrosis (IPN) in patients with acute pancreatitis (AP).  Methods  A retrospective analysis was performed for the clinical data of 219 patients with moderate-severe acute pancreatitis (MSAP) and 53 patients with severe acute pancreatitis (SAP) who were admitted to The Affiliated Hospital of Southwest Medical University from June 2019 to June 2020, and according to the presence or absence of systemic inflammatory response syndrome (SIRS) at the initial stage of the disease, they were divided into SIRS group with 160 patients and non-SRIS group with 112 patients. Baseline data, serological markers, complications, and mortality rate were included for analysis. The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups; the chi-square test was used for comparison of categorical data between multiple groups, and the Bonferroni method was used for further comparison between two groups. A logistic regression analysis was used to screen out valuable variables; the receiver operating characteristic (ROC) curve was used to compare the diagnostic value of variables, and the Z-test was used for pairwise comparison of area under the ROC curve (AUC).  Results  Compared with the non-SIRS group, the SIRS group had significantly higher white blood cell count (WBC), C-reactive protein (CRP), and procalcitonin (all P < 0.05) and a significantly higher proportion of patients with acute peripancreatic necrosis (ANC), IPN, pancreatic necrosis (PN), organ dysfunction, multiple organ dysfunction syndrome (MODS), SAP, critically-ill acute pancreatitis (CAP), death, BISAP score > 2, CTSI score > 2, or RANSON score > 2 (all P < 0.05). The univariate analysis showed that SIRS duration, obesity, CRP, WBC, blood urea nitrogen, PN, ANC, SAP, MODS, RANSON score, BISAP score, and CTSI score were risk factors for IPN in patients with AP (all P < 0.05), and the multivariate analysis showed that SIRS duration (odds ratio [OR]=1.307, 95% confidence interval [CI]: 1.081-1.580, P=0.006) and ANC (OR=42.247, 95% CI: 10.829-164.818, P < 0.001) were risk factors for IPN; when ANC was excluded, SIRS duration (OR=1.430, 95% CI: 1.207-1.694, P < 0.001) and PN (OR=5.296, 95% CI: 1.845-15.203, P=0.002) were risk factors for IPN. The ROC curve showed that SIRS duration (AUC=0.772, Youden index=0.521), RANSON score (AUC=0.701, Youden index=0.319), BISAP score (AUC=0.741, Youden index=0.377), and CTSI score (AUC=0.765, Youden Index=0.414) had a certain value in predicting IPN, and there was no significant difference in AUC between any two indices. The long-duration SIRS group (> 4 d) had a significantly higher proportion of patients with PN, ANC, IPN, SAP, or CAP than the non-SIRS group (0 d), the transient SIRS group (1~2 d), and the persistent SIRS group (3~4 d) (all P < 0.05), and the persistent SIRS group had a significantly higher proportion of patients with SAP than the non-SIRS group (P < 0.05).  Conclusion  AP patients with SIRS in the early stage are likely to develop organ failure and local complications, and there is a significant increase in the risk of IPN when SIRS duration is > 4.5 days.

     

  • [1]
    Pancreas Study Group, Chinese Society of Gastroenterology, Chinese Medical Association; Editorial Board of Chinese Journal of Pancreatology; Editorial Board of Chinese Journal of Digestion. Chinese guidelines for the management of acute pancreatitis (Shenyang, 2019)[J]. J Clin Hepatol, 2019, 35(12): 2706-2711. (in Chinese)

    中华医学会消化病学分会胰腺疾病学组, 《中华胰腺病杂志》编委会, 《中华消化杂志》编委会. 中国急性胰腺炎诊治指南(2019年, 沈阳)[J]. 临床肝胆病杂志, 2019, 35(12): 2706-2711.
    [2]
    LEPPÄNIEMI A, TOLONEN M, TARASCONI A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis[J]. World J Emerg Surg, 2019, 14: 27. DOI: 10.1186/s13017-019-0247-0
    [3]
    TAN C, YANG L, SHI F, et al. Early systemic inflammatory response syndrome duration predicts infected pancreatic necrosis[J]. J Gastrointest Surg, 2020, 24(3): 590-597. DOI: 10.1007/s11605-019-04149-5
    [4]
    SILVA-VAZ P, ABRANTES AM, MORGADO-NUNES S, et al. Evaluation of prognostic factors of severity in acute biliary pancreatitis[J]. Int J Mol Sci, 2020, 21(12) : 4300. DOI: 10.3390/ijms21124300
    [5]
    VENKATESH NR, VIJAYAKUMAR C, BALASUBRAMANIYAN G, et al. Comparison of different scoring systems in predicting the severity of acute pancreatitis: A prospective observational study[J]. Cureus, 2020, 12(2): e6943. http://www.researchgate.net/publication/339176836_Comparison_of_Different_Scoring_Systems_in_Predicting_the_Severity_of_Acute_Pancreatitis_A_Prospective_Observational_Study
    [6]
    SOULOUNTSI V, SCHIZODIMOS T. Use of antibiotics in acute pancreatitis: Ten major concerns[J]. Scand J Gastroenterol, 2020, 55(10): 1211-1218. DOI: 10.1080/00365521.2020.1804995
    [7]
    CASE BM, JENSEN KK, BAKIS G, et al. Endoscopic interventions in acute pancreatitis: What the advanced endoscopist wants to know[J]. Radiographics, 2018, 38(7): 2002-2018. DOI: 10.1148/rg.2018180066
    [8]
    ARVANITAKIS M, DUMONCEAU JM, ALBERT J, et al. Endoscopic management of acute necrotizing pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) evidence-based multidisciplinary guidelines[J]. Endoscopy, 2018, 50(5): 524-546. DOI: 10.1055/a-0588-5365
    [9]
    TRIKUDANATHAN G, WOLBRINK D, van SANTVOORT HC, et al. Current concepts in severe acute and necrotizing pancreatitis: An evidence-based approach[J]. Gastroenterology, 2019, 156(7): 1994-2007. DOI: 10.1053/j.gastro.2019.01.269
    [10]
    SHARMA D, JAKKAMPUDI A, REDDY R, et al. Association of systemic inflammatory and anti-inflammatory responses with adverse outcomes in acute pancreatitis: Preliminary results of an ongoing study[J]. Dig Dis Sci, 2017, 62(12): 3468-3478. DOI: 10.1007/s10620-017-4813-6
    [11]
    SENDLER M, van den BRANDT C, GLAUBITZ J, et al. NLRP3 inflammasome regulates development of systemic inflammatory response and compensatory anti-inflammatory response syndromes in mice with acute pancreatitis[J]. Gastroenterology, 2020, 158(1): 253-269. DOI: 10.1053/j.gastro.2019.09.040
    [12]
    YANG R, TENHUNEN J, TONNESSEN TI. HMGB1 and histones play a significant role in inducing systemic inflammation and multiple organ dysfunctions in severe acute pancreatitis[J]. Int J Inflam, 2017, 2017: 1817564. http://www.ncbi.nlm.nih.gov/pubmed/28316860
    [13]
    CHEN Z, DONG WH, WU Q, et al. Two-layer regulation of TRAF6 mediated by both TLR4/NF-kB signaling and miR-589-5p increases proinflammatory cytokines in the pathology of severe acute pancreatitis[J]. Am J Transl Res, 2020, 12(6): 2379-2395. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_american-journal-translational-research_thesis/040006415721.html
    [14]
    IYER S, BAWA EP, TARIQUE M, et al. Know thy enemy-understanding the role of inflammation in severe acute pancreatitis[J]. Gastroenterology, 2020, 158(1): 46-48. DOI: 10.1053/j.gastro.2019.11.039
    [15]
    DIXIT A, CHEEMA H, GEORGE J, et al. Extracellular release of ATP promotes systemic inflammation during acute pancreatitis[J]. Am J Physiol Gastrointest Liver Physiol, 2019, 317(4): g463-g475. DOI: 10.1152/ajpgi.00395.2018
    [16]
    DUMNICKA P, MADUZIA D, CERANOWICZ P, et al. The interplay between inflflammation, coagulation and endothelial injury in the early phase of acute pancreatitis: Clinical implications[J]. Int J Mol Sci, 2017, 18(2): 354. DOI: 10.3390/ijms18020354
    [17]
    GAD MM, SIMONS-LINARES CR. Is aggressive intravenous fluid resuscitation beneficial in acute pancreatitis? A meta-analysis of randomized control trials and cohort studies[J]. World J Gastroenterol, 2020, 26(10): 1098-1106. DOI: 10.3748/wjg.v26.i10.1098
    [18]
    YE B, MAO W, CHEN Y, et al. Aggressive resuscitation is associated with the development of acute kidney injury in acute pancreatitis[J]. Dig Dis Sci, 2019, 64(2): 544-552. DOI: 10.1007/s10620-018-5328-5
    [19]
    CHOOSAKUL S, HARINWAN K, CHIRAPONGSATHORN S, et al. Comparison of normal saline versus Lactated Ringer's solution for fluid resuscitation in patients with mild acute pancreatitis, A randomized controlled trial[J]. Pancreatology, 2018, 18(5): 507-512. DOI: 10.1016/j.pan.2018.04.016
    [20]
    FROGHI F, SOGGIU F, RICCIARDI F, et al. Ward-based goal-directed fluid therapy (GDFT) in acute pancreatitis (GAP) trial: Study protocol for a feasibility randomised controlled trial[J]. BMJ Open, 2019, 9(10): e028783. DOI: 10.1136/bmjopen-2018-028783
    [21]
    WOLBRINK D, GRUNDSELL JR, WITTEMAN B, et al. Are omega-3 fatty acids safe and effective in acute pancreatitis or sepsis? A systematic review and meta-analysis[J]. Clin Nutr, 2020, 39(9): 2686-2694. DOI: 10.1016/j.clnu.2019.12.006
    [22]
    RUIZ-REBOLLO ML, MUÑOZ-MORENO MF, MAYO-ISCAR A, et al. Statin intake can decrease acute pancreatitis severit[J]. Pancreatology, 2019, 19(6): 807-812. DOI: 10.1016/j.pan.2019.07.004
    [23]
    JIANG X, SHI JY, WANG XY, et al. The impacts of infectious complications on outcomes in acute pancreatitis: A retrospective study[J]. Mil Med Res, 2020, 7(1): 38. http://www.researchgate.net/publication/343685598_The_impacts_of_infectious_complications_on_outcomes_in_acute_pancreatitis_a_retrospective_study
    [24]
    TIAN H, CHEN L, WU X, et al. Infectious complications in severe acute pancreatitis: Pathogens, drug resistance, and status of nosocomial infection in a university-affiliated teaching hospital[J]. Dig Dis Sci, 2020, 65(7): 2079-2088. DOI: 10.1007/s10620-019-05924-9
    [25]
    BARON TH, DIMAIO CJ, WANG AY, et al. American Gastroenterological association clinical practice update: Management of pancreatic necrosis[J]. Gastroenterology, 2020, 158(1): 67-75. DOI: 10.1053/j.gastro.2019.07.064
    [26]
    SUSAK YM, DIRDA OO, FEDORCHUK OG, et al. Infectious complications of acute pancreatitis is associated with peripheral blood phagocyte functional exhaustion[J]. Dig Dis Sci, 2020.[Online ahead of print]
    [27]
    LU JD, CAO F, DING YX, et al. Timing, distribution, and microbiology of infectious complications after necrotizing pancreatitis[J]. World J Gastroenterol, 2019, 25(34): 5162-5173. DOI: 10.3748/wjg.v25.i34.5162
    [28]
    AUSANIA F, SENRA DEL RÍO P, BORIN A, et al. Factors associated with mortality in patients with infected pancreatic necrosis: The "surgery effect"[J]. Updates Surg, 2020, 72(4): 1097-1103. DOI: 10.1007/s13304-020-00764-z
    [29]
    ZHANG ZH, DING YX, WU YD, et al. A meta-analysis and systematic review of percutaneous catheter drainage in treating infected pancreatitis necrosis[J]. Medicine (Baltimore), 2018, 97(47): e12999. DOI: 10.1097/MD.0000000000012999
    [30]
    DARRIVERE L, LAPIDUS N, COLIGNON N, et al. Minimally invasive drainage in critically ill patients with severe necrotizing pancreatitis is associated with better outcomes: An observational study[J]. Crit Care, 2018, 22(1): 321. DOI: 10.1186/s13054-018-2256-x
    [31]
    SUN B, LI GQ. Surgical intervention strategies for local complications of severe acute pancreatitis[J]. Chin J Dig Surg, 2020, 19(4): 379-383. (in Chinese)
  • Relative Articles

    [1]Chenlu HAN, Haijun LIANG, Daokun YANG, Haiyan CHANG, Shuai WEI, Xingwei WANG, Haili GAO. Expression levels of serum high-mobility group box 1, soluble CD163, and prostaglandin E2 in patients with hepatitis B virus-related chronic-on-acute liver failure and their value in predicting prognosis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1130-1135. doi: 10.12449/JCH240610
    [2]Pu MinJing, Zhao HongXian, Bo Chao, Zhou XiangYu, Chen Xia. Role and mechanism of the high-mobility group box 1/Toll-like receptor 9 signaling pathway in intestinal mucosal barrier injury in severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1037-1040. doi: 10.3969/j.issn.1001-5256.2019.05.020
    [3]Zhang PanPan, Wang Song, Meng XiangWei, Hua Rui. A case of chronic hepatitis B with mesenteric vasculitis[J]. Journal of Clinical Hepatology, 2017, 33(2): 334-335. doi: 10.3969/j.issn.1001-5256.2017.02.028
    [4]Zhang QingShan, Zhao SuXian, Ren WeiGuang, Kong Li. Chronic hepatitis B with bile duct hamartomas in the liver: a case report[J]. Journal of Clinical Hepatology, 2017, 33(10): 1990-1991. doi: 10.3969/j.issn.1001-5256.2017.10.029
    [5]Zhang ZeTian, Ji HuiFan, Chen Shuai, Li Xu, Yang WenXuan, Zhang GuoShan, Guo XiaoLin. Clinical cure of chronic hepatitis B: a case report[J]. Journal of Clinical Hepatology, 2016, 32(8): 1578-1579. doi: 10.3969/j.issn.1001-5256.2016.08.030
    [6]Wang Fang, Quan ZuoHua, Yang XingKun, Kou JunFeng, Yun ShengHao, Cai GuoFang, Zhou XinRen. Influence of antiviral therapy with telbivudine on serum soluble complement receptor type 1 in patients with chronic hepatitis B or liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1118-1120. doi: 10.3969/j.issn.1001-5256.2016.06.019
    [7]Li PingYing, Yang YongGeng, Ma YingCai, Lu LunGen. Adult chronic hepatitis B with acute lymphoblastic leukemia: a case report and literature review[J]. Journal of Clinical Hepatology, 2015, 31(11): 1894-1896. doi: 10.3969/j.issn.1001-5256.2015.11.031
    [8]Wang RongQi, Nan YueMin. Neutropenia caused by telbivudine in chronic hepatitis B patients: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(2): 273-274. doi: 10.3969/j.issn.1001-5256.2015.02.031
    [9]Zhang DaLi, Zhang Min, Su HaiBin. One case of hepatitis B cirrhosis complicated by rhabdomyolysis[J]. Journal of Clinical Hepatology, 2015, 31(3): 434-435. doi: 10.3969/j.issn.1001-5256.2015.03.028
    [10]Wu LieXiu, Lin ShuMei, Zhang Xi, Zheng ShuQin, Ye Feng, Chen TianYan, Zhao YingRen, Zhang ShuLin. Dynamic changes in B7- H1 expression on peripheral blood mononuclear cells in chronic hepatitis B patients treated with entecavir[J]. Journal of Clinical Hepatology, 2014, 30(9): 929-931. doi: 10.3969/j.issn.1001-5256.2014.09.023
    [11]Li ZePeng, Zhao PengTao, Chi XiaoLing, Xiao HuanMing, Xie YuBao. One case of hepatic cirrhosis with tuberculous pleurisy[J]. Journal of Clinical Hepatology, 2014, 30(1): 74-74. doi: 10.3969/j.issn.1001-5256.2014.01.021
    [12]Ding TiLong, Fan XiuMei, Wang Yong, Huang YiJiang, Ma Yong. Expression of hypoxia-inducible factor-1  α in liver tissues of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(2): 124-127.
    [13]Li Juan, Tian Jie, Han Tao, Wei Su. Chronic hepatitis B with adefovir-associated renal insufficiency: a case report[J]. Journal of Clinical Hepatology, 2012, 28(12): 956-957.
    [14]Hepatobiliary Disease Group, Internal Medicine of Traditional Chinese, China Association of Traditional Chinese Medicine, Expert Consensus of Hepatology, World Federation of Chinese Medicine Societies, Hepatology Group, Chinese Association of the Integration of Traditional and Western Medicine. Guidelines for traditional Chinese medical diagnosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2012, 28(3): 164-168.
    [15]Li ChunXia, Pan HuaiQiang, Li YanJun, Xu GuangHua, Chen YanPing, Feng JiHong, Wei Hua, Ceng QingLei. One case report of occult hepatitis B infection[J]. Journal of Clinical Hepatology, 2012, 28(1): 66-68.
    [16]Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
    [17]Li Man, Ceng ZhenJun, Sun XueHua, Zhu XiaoJun, Zhou ZhenHua, Gao YueQiu. The correlational study of the relationship between the fibrosin expression in peripheral blood and hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(12): 1312-1315+1317.
    [18]Niu ChunYan, Zheng JianYun, Li Lei, Gao BaoHua, Liu Bing, Luo JianMei. The expression and significance of HMGB1 in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(8): 807-809.
    [19]Zhang Zhe, Guo JinSheng. The role of high mobility group box 1 in human liver diseases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1116-1120.
    [20]Gao BaoHua, Wang Wen, Niu ChunYan, Zheng JianYun, Liu Bing, Luo JianMei. The expression of HMGB1 in hepatocellular carcinoma, paracancerous liver tissue and its significance[J]. Journal of Clinical Hepatology, 2011, 27(8): 850-853.
  • Cited by

    Periodical cited type(12)

    1. 张倩落,马赟,杨国祥,王宏利,贾庶捷. 安络化纤丸联合硫普罗宁治疗慢性乙型肝炎肝硬化的临床研究. 现代药物与临床. 2024(02): 412-417 .
    2. 谢娇娇,何燕芳,马燕花,郭才,郑兰兰. 肝硬化患者血清高迁移率族蛋白B水平变化及其与肠黏膜通透性的相关性. 山东医药. 2024(15): 9-12 .
    3. 刘俊香,毕泗朕. 血清GP73、HMGB1、FLP1、sST2与慢性乙型病毒性肝炎患者 HBV-DNA载量、肝功能及肝纤维化标志物的相关性分析. 检验医学与临床. 2023(06): 787-791 .
    4. 陆燕夏,唐秀娇,郑成芳,王月琴. 血清ANGPTL2、sVAP-1、HMGB1在慢性乙型肝炎诊断中的价值. 国际检验医学杂志. 2022(11): 1325-1328 .
    5. 陈婷婷,储建华,杨丽,周宝勤. HMGB-1、PDGF-BB和PTAR水平对慢性乙型肝炎肝硬化病情程度和疾病预后的评估价值. 现代消化及介入诊疗. 2022(10): 1318-1322 .
    6. 徐静,张凤岐,王聪,陈磊,郭锋. 血清miR-223、HMGB1与乙肝患者HBV-DNA载量和肝功能的关系研究. 国际病毒学杂志. 2021(04): 332-335 .
    7. 何伟锋. 研究慢性乙型肝炎合并非酒精性脂肪性肝病患者的肝组织纤维化水平与脂质负荷的关系. 名医. 2020(09): 58-59 .
    8. 许日新,林俊芳,邓雅丽. 慢性乙型肝炎肝硬化患者微生态制剂联合抗病毒药物治疗效果及机体免疫功能的变化. 慢性病学杂志. 2020(12): 1798-1801 .
    9. 杜刚,王永利,冯雅. 腹腔镜下左半肝切除术与恩度联合治疗肝癌患者的效果及对血清HMGB1和TK1水平的影响. 临床和实验医学杂志. 2019(17): 1874-1879 .
    10. 邓崇君,陆文烈. 探讨替比夫定与恩替卡韦治疗乙型肝炎病毒感染的临床疗效及对炎症因子的影响. 北方药学. 2019(12): 116-117 .
    11. Chunli TANG,Jiangcun WEI,Zhen XIE,Meiyan QIU,Jiabao MA,Fengxian ZHAO,Hongxia CHEN. Water Extraction Process of Chinese Herbal Compound Man Gan Ning. Medicinal Plant. 2019(06): 60-65 .
    12. 姚传霞,汪茂荣. 高迁移率族蛋白-1的生物学特性及其在HBV相关肝病发生、发展和治疗中的作用. 临床肝胆病杂志. 2019(12): 2788-2792 . 本站查看

    Other cited types(2)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04010203040
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 9.5 %FULLTEXT: 9.5 %META: 87.8 %META: 87.8 %PDF: 2.6 %PDF: 2.6 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 4.5 %其他: 4.5 %其他: 1.7 %其他: 1.7 %Baden: 0.5 %Baden: 0.5 %Ikeda: 0.5 %Ikeda: 0.5 %India: 0.2 %India: 0.2 %[]: 0.5 %[]: 0.5 %上海: 4.5 %上海: 4.5 %兰州: 0.2 %兰州: 0.2 %加泰罗尼亚自治区: 0.8 %加泰罗尼亚自治区: 0.8 %北京: 11.5 %北京: 11.5 %南宁: 0.5 %南宁: 0.5 %台州: 0.2 %台州: 0.2 %吉林: 0.6 %吉林: 0.6 %哥伦布: 0.2 %哥伦布: 0.2 %安卡拉: 0.6 %安卡拉: 0.6 %张家口: 7.8 %张家口: 7.8 %杭州: 0.9 %杭州: 0.9 %武汉: 0.9 %武汉: 0.9 %芒廷维尤: 36.3 %芒廷维尤: 36.3 %芝加哥: 0.5 %芝加哥: 0.5 %莫斯科: 1.2 %莫斯科: 1.2 %西宁: 25.1 %西宁: 25.1 %贵港: 0.2 %贵港: 0.2 %长春: 0.3 %长春: 0.3 %长治: 0.2 %长治: 0.2 %其他其他BadenIkedaIndia[]上海兰州加泰罗尼亚自治区北京南宁台州吉林哥伦布安卡拉张家口杭州武汉芒廷维尤芝加哥莫斯科西宁贵港长春长治

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Article Metrics

    Article views (727) PDF downloads(59) Cited by(14)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return